Eliem Therapeutics Total Non-Operating Income/Expense 2021-2024 | CLYM
Eliem Therapeutics total non-operating income/expense from 2021 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Eliem Therapeutics Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$5 |
| 2022 |
$-0 |
| 2021 |
$-12 |
| 2020 |
$0 |
Eliem Therapeutics Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$-1 |
| 2022-06-30 |
$-1 |
| 2022-03-31 |
$-0 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$-0 |
| 2021-06-30 |
$-0 |
| 2021-03-31 |
$-12 |
| 2020-12-31 |
|
| 2020-09-30 |
$0 |
| 2020-06-30 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
